BR112017003263A2 - anticorpos anti-vasa, e métodos de produção e utilização dos mesmos - Google Patents

anticorpos anti-vasa, e métodos de produção e utilização dos mesmos

Info

Publication number
BR112017003263A2
BR112017003263A2 BR112017003263A BR112017003263A BR112017003263A2 BR 112017003263 A2 BR112017003263 A2 BR 112017003263A2 BR 112017003263 A BR112017003263 A BR 112017003263A BR 112017003263 A BR112017003263 A BR 112017003263A BR 112017003263 A2 BR112017003263 A2 BR 112017003263A2
Authority
BR
Brazil
Prior art keywords
vasa
mabs
methods
production
antibodies
Prior art date
Application number
BR112017003263A
Other languages
English (en)
Inventor
Zhang Bo
T Weaver David
Original Assignee
Ovascience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovascience Inc filed Critical Ovascience Inc
Publication of BR112017003263A2 publication Critical patent/BR112017003263A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/04—Hydrolases acting on acid anhydrides (3.6) acting on acid anhydrides; involved in cellular and subcellular movement (3.6.4)
    • C12Y306/04013—RNA helicase (3.6.4.13)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

a presente invenção refere-se a anticorpos (mabs) anti-vasa, particularmente mabs humanizados que ligam especificamente a vasa com alta afinidade, são descritas. as sequências de aminoácidos das cdrs das cadeias leves e das cadeias pesadas, bem como sequências de consenso para estas cdrs, destes mabs anti-vasa são fornecidas. a descrição também fornece moléculas de ácido nucleico codificando os mabs anti-vasa, vetores de expressão, células hospedeiras, métodos para produzir os mabs anti-vasa, e métodos para expressar os mabs anti-vasa. finalmente, são fornecidos métodos de uso dos mabs anti-vasa para isolar e/ou purificar células expressando vasa.
BR112017003263A 2014-09-16 2015-09-16 anticorpos anti-vasa, e métodos de produção e utilização dos mesmos BR112017003263A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462051130P 2014-09-16 2014-09-16
US201462089054P 2014-12-08 2014-12-08
PCT/US2015/050449 WO2016044436A2 (en) 2014-09-16 2015-09-16 Anti-vasa antibodies, and methods of production and use thereof

Publications (1)

Publication Number Publication Date
BR112017003263A2 true BR112017003263A2 (pt) 2017-11-28

Family

ID=55454121

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017003263A BR112017003263A2 (pt) 2014-09-16 2015-09-16 anticorpos anti-vasa, e métodos de produção e utilização dos mesmos

Country Status (26)

Country Link
US (4) US9403913B2 (pt)
EP (1) EP3194448A4 (pt)
JP (2) JP2017532953A (pt)
KR (1) KR20170056521A (pt)
CN (1) CN106573985A (pt)
AP (1) AP2017009758A0 (pt)
AU (1) AU2015317813B2 (pt)
BR (1) BR112017003263A2 (pt)
CA (1) CA2959179A1 (pt)
CL (1) CL2017000402A1 (pt)
CO (1) CO2017001724A2 (pt)
CR (1) CR20170067A (pt)
DO (1) DOP2017000050A (pt)
EA (1) EA201790236A1 (pt)
EC (1) ECSP17011262A (pt)
GT (1) GT201700036A (pt)
IL (1) IL250451A0 (pt)
MX (1) MX358243B (pt)
NI (1) NI201700022A (pt)
PE (1) PE20170667A1 (pt)
PH (1) PH12017500309A1 (pt)
SG (1) SG11201701016WA (pt)
SV (1) SV2017005393A (pt)
TN (1) TN2017000066A1 (pt)
TW (1) TW201619194A (pt)
WO (1) WO2016044436A2 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2494108C2 (ru) 2006-04-07 2013-09-27 Аерпио Терапетикс, Инк. Антитела, которые связывают человеческий белок бета-тирозин фосфатазу (нртрвета), и их использование
CR20170067A (es) * 2014-09-16 2017-05-10 Ovascience Inc Anticuerpos anti-vasa y metodos de producción y uso de los mismos
MX2019000727A (es) 2016-07-20 2019-05-02 Aerpio Therapeutics Inc Anticuerpos monoclonales humanizados que tienen como blanco ve-ptp (hptp-b).
CN113164597A (zh) 2018-09-24 2021-07-23 爱尔皮奥制药公司 靶向HPTP-β（VE-PTP）和VEGF的多特异性抗体
WO2020102565A2 (en) 2018-11-14 2020-05-22 Flagship Pioneering Innovations V, Inc. Systems and methods for nondestructive testing of gametes
WO2021096829A1 (en) * 2019-11-11 2021-05-20 Vanderbilt University Human monoclonal antibodies to hantavirus and methods of use therefor

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996039518A1 (en) * 1995-06-05 1996-12-12 Bionebraska, Inc. Lead binding polypeptides and nucleotides coding therefor
WO2001036445A1 (en) * 1999-11-18 2001-05-25 The Brigham And Women's Hospital, Inc. Compositions and methods for the improved diagnosis and treatment of germ cell tumors
US6875854B1 (en) * 1999-11-18 2005-04-05 The Brigham And Women's Hospital, Inc. Compositions and methods for the improved diagnosis and treatment of germ cell tumors
US7955846B2 (en) 2004-05-17 2011-06-07 The General Hospital Corporation Compositions comprising female germline stem cells and methods of use thereof
AU2005257839A1 (en) 2004-05-17 2006-01-05 The General Hospital Corporation Methods and compositions for producing germ cells from bone marrow derived germline stem cells
MY145073A (en) * 2004-07-09 2011-12-15 Chugai Pharmaceutical Co Ltd Anti-glypican 3 antibody
US20090061485A1 (en) * 2004-12-22 2009-03-05 Chugai Seiyaku Kabushiki Kaisha Method of Producing an Antibody Using a Cell in Which the Function of Fucose Transporter Is Inhibited
AU2009297872A1 (en) 2008-09-25 2010-04-01 National University Corporation Tokyo University Of Marine Science And Technology Anti-tuna Vasa antibody
WO2010074192A1 (ja) * 2008-12-26 2010-07-01 国立大学法人東京大学 抗lgr7抗体を用いる癌の診断および治療
ES2624835T3 (es) * 2009-08-06 2017-07-17 Immunas Pharma, Inc. Anticuerpos que se unen específicamente a los oligómeros A beta y uso de los mismos
WO2012142500A2 (en) 2011-04-14 2012-10-18 The General Hospital Corporation Compositions and methods for autologous germline mitochondrial energy transfer
EA201490050A1 (ru) * 2011-06-29 2014-07-30 Зе Дженерэл Хоспитэл Корпорейшн Композиции и способы повышения биоэнергетического состояния женских зародышевых клеток
CN105026425A (zh) * 2012-12-31 2015-11-04 财团法人生物技术开发中心 抗颗粒溶解素抗体、方法及其应用
CR20170067A (es) * 2014-09-16 2017-05-10 Ovascience Inc Anticuerpos anti-vasa y metodos de producción y uso de los mismos
US20180002662A1 (en) * 2015-01-13 2018-01-04 President And Fellows Of Harvard College Purification of germ stem cells by targeting mrp9

Also Published As

Publication number Publication date
AU2015317813A1 (en) 2017-03-02
TN2017000066A1 (en) 2018-07-04
CO2017001724A2 (es) 2017-07-19
WO2016044436A3 (en) 2016-06-09
MX358243B (es) 2018-08-10
DOP2017000050A (es) 2018-04-15
TW201619194A (zh) 2016-06-01
CN106573985A (zh) 2017-04-19
US20160075797A1 (en) 2016-03-17
GT201700036A (es) 2018-12-19
MX2017002390A (es) 2017-07-28
US9567404B2 (en) 2017-02-14
SG11201701016WA (en) 2017-03-30
ECSP17011262A (es) 2017-05-31
US20180155445A1 (en) 2018-06-07
EA201790236A1 (ru) 2017-11-30
US20170107299A1 (en) 2017-04-20
PE20170667A1 (es) 2017-06-06
AP2017009758A0 (en) 2017-02-28
KR20170056521A (ko) 2017-05-23
JP2018148915A (ja) 2018-09-27
CR20170067A (es) 2017-05-10
IL250451A0 (en) 2017-03-30
PH12017500309A1 (en) 2017-07-10
US9403913B2 (en) 2016-08-02
EP3194448A2 (en) 2017-07-26
SV2017005393A (es) 2017-06-07
CA2959179A1 (en) 2016-03-24
NI201700022A (es) 2017-05-04
CL2017000402A1 (es) 2017-11-03
AU2015317813B2 (en) 2018-04-05
EP3194448A4 (en) 2018-03-14
WO2016044436A2 (en) 2016-03-24
US20160311929A1 (en) 2016-10-27
JP2017532953A (ja) 2017-11-09

Similar Documents

Publication Publication Date Title
CY1123932T1 (el) Δομες πολυειδικου αντισωματος
BR112017003263A2 (pt) anticorpos anti-vasa, e métodos de produção e utilização dos mesmos
CO2018012415A2 (es) Proteínas de unión específica y usos de las mismas
BR112017006736A2 (pt) anticorpos antimiostatina, polipeptídeos contendo regiões fc variantes, e métodos de utilização
BR112018011073A2 (pt) anticorpos antimiostatina, polipeptídeos contendo regiões fc variantes e métodos de utilização
BR112018006547A2 (pt) anticorpos de pd-1 e usos dos mesmos
BR112017025564A2 (pt) anticorpos anti-ctla-4 e métodos de uso dos mesmos
EA201492101A1 (ru) Антитела против fcrn
EA201591814A1 (ru) БИСПЕЦИФИЧЕСКИЕ МОЛЕКУЛЫ Fc
PE20210107A1 (es) Anticuerpos anti-cd3 y metodos de uso
CR20170032A (es) Moleculas biespecíficas de unión a antígeno activadoras de células t
PH12015501651B1 (en) Antibody constructs for cdh19 and cd3
EA201792080A1 (ru) Гуманизированные анти-c1s антитела и способы их применения
EA201690992A1 (ru) Антитела, специфичные к fcrn
CO2020004200A2 (es) Anticuerpo monoclonal anti-il-5rα
SA517390221B1 (ar) Igf-1r الجسم المضاد لـ واستخدامه في تشخيص سرطان
EA202092283A1 (ru) Конструкции антител к cdh19 и cd3

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]